FDA, EMA and MHRA pathways mapped from pre-IND to post-market — so every study you run also builds your approval case.

Protocols, endpoints and adaptive designs built for statistical rigour and operational reality — fewer amendments, faster reads.

Validation, evidence and governance for machine-learning medical devices — from algorithm locking to real-world performance monitoring.

Value stories, pricing corridors and real-world evidence that withstand HTA scrutiny in the markets that matter to your launch.

Tech transfer, GMP readiness and supply resilience for biologics, cell & gene therapies and complex small molecules.

Independent scientific, clinical and commercial diligence for investors, boards and business-development teams.